Drug lookup
Drug reference

Pentostatin

Antimetabolite · Antineoplastic

Also known as Nipent, 2′-deoxycoformycin

AntimetaboliteAntineoplastic
CDSCO approved
EXCRETION
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Avoid (teratogenic in animal studies).
FDA category + note
Top interactionssee all 12
  • Fludarabine PhosphateSevereTextbookG&G 14e
  • AdalimumabSevereDatabaseDDInter
  • BaricitinibSevereDatabaseDDInter
  • CertolizumabSevereDatabaseDDInter

Mechanism

Pentostatin (2'-deoxycoformycin) is a potent irreversible inhibitor of adenosine deaminase (ADA), the enzyme that catalyzes the deamination of adenosine and deoxyadenosine. ADA inhibition causes intracellular accumulation of deoxyadenosine triphosphate (dATP), which inhibits ribonucleotide reductase and S-adenosylhomocysteine hydrolase, leading to impaired DNA synthesis and apoptosis. Lymphocytes are particularly sensitive because of their high ADA activity and dependence on the purine salvage pathway, making pentostatin highly effective in hairy cell leukemia.

Indications

Hairy cell leukaemia (initiated in specialist centres)Chronic lymphocytic leukemiaSmall cell non-Hodgkin's lymphomaHairy cell leukemia

Dosing

Adult
To be given by intravenous injection or intravenous infusion on alternate weeks (consult product literature)
Renal adjustment
Avoid if creatinine clearance less than 60 mL/minute

Pharmacokinetics

Half-life
5.7 h (mean terminal t1/2)
Excretion
Almost entirely by renal excretion.

Contraindications

  • Creatinine clearance less than 60 mL/minute
  • Men should not father children during and for 6 months after treatment

Side effects

Common
Agranulocytosisalopeciaamenorrhoeaanaemiaangina pectorisanxietyappetite decreasedarrhythmiasarthritisastheniaasthmaatrioventricular blockblood disorderbone disorderbone marrow disordersbreast masscardiac arrestchest painchillsconfusionconstipationcoughdeafnessdeathdepersonalisationdepressiondiarrhoeadizzinessdrowsinessdry eyedry mouthdysarthriadysphagiadyspnoeaear painelectrolyte imbalanceembolism and thrombosisemotional labilityeosinophiliaeye disorderseye inflammationeye painfebrile neutropeniafeverfluid imbalanceflushinggastrointestinal discomfortgastrointestinal disordersgoutgraft versus host diseasehaemorrhagehallucinationhangoverheadachesheart failurehostilityhyperbilirubinaemiahyperglycaemiahyperhidrosishypersensitivityhypertensionhypotensionincreased risk of infectioninfluenza like illMyelosuppressionGastrointestinal symptomsSkin rashesAbnormal liver function studiesNeutropenic fever
Serious
  • Myelosuppression
  • Immunosuppression
  • Severe rash
  • Neurotoxicity
  • Thromboembolism
  • Agranulocytosis
  • Anaemia
  • Blood disorder
  • Bone marrow disorders
  • Cardiac arrest
  • Death
  • Embolism and thrombosis
  • Febrile neutropenia
  • Haemorrhage
  • Heart failure
  • Increased risk of infection
  • Opportunistic infections (due to depletion of normal T cells)
  • Major renal complications (at high doses)
  • Neurological complications (at high doses)
  • Pulmonary toxicity (in combination with fludarabine phosphate)

Pregnancy & lactation

Pregnancy

Avoid (teratogenic in animal studies).

Lactation

Discontinue breast-feeding.

Drug interactions

Fludarabine Phosphate
Severe
Textbook

Severe or even fatal pulmonary toxicity.

Avoid combination due to severe pulmonary toxicity.

Source: G&G 14e

Adalimumab
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Baricitinib
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Certolizumab
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Cladribine
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Clozapine
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Deferiprone
Severe
Database

Clinical effect not specified

Source: DDInter

Etanercept
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Fingolimod
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Fludarabine
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Golimumab
Severe
Database

Clinical effect not specified

Source: DDInter

Infliximab
Severe
Database

Clinical effect not specified

Source: DDInter

Related guidelines

Other Antimetabolite drugs

Ask House about Pentostatin

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: Goodman & Gilman 14e, Katzung·Verified: 2026-05-10 · House clinical team